Treats CMV retinitis. ANDA 206876, held by Dr Reddys. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 206876 (Valganciclovir Hydrochloride), held by Dr Reddys, was first approved by FDA on Dec 12, 2017, with 3 approved supplements and 0 published complete response letters.
Valganciclovir tablet is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 12, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Rx |
| May 13, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 13, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 23, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 12, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters